ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Liver Evaluation for Heart Transplantation: Which Is Better, Noninvasive Scans or Liver Biopsy?

R. Mohan, J. Patel, M. Kittleson, D. Chang, T. Aintablian, L. Czer, F. Esmailian, J. Kobashigawa.

Cedars-Sinai Heart Institute, Los Angeles, CA.

Meeting: 2016 American Transplant Congress

Abstract number: B163

Keywords: Heart/lung transplantation, High-risk

Session Information

Date: Sunday, June 12, 2016

Session Name: Poster Session B: Hearts and VADs in Depth - The Force Awakens

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Related Abstracts
  • Predictive Value of Regadenoson Scans After Heart Transplant
  • The Impact of Complement Binding Donor Specific Antibodies in the First Year After Heart Transplantation.

Background: Patients awaiting heart transplantation who have known liver disease from congestive hepatopathy are at increased risk for mortality post-transplantation. The evaluation of the liver in these patients is difficult as the liver scans and even the liver biopsy (Bx) may not be representative of the true pathology. We decided to assess our patients being evaluated for transplant with known congestive hepatopathy who had both liver scans by either ultrasound (US) or computerized tomography (CT) scans, and liver Bx. All patients underwent heart transplant and outcomes were assessed for patients with liver abnormalities.

Methods: Between Jan 2010 and Dec 2013 we evaluated 22 patients who had known congestive hepatopathy. Patients were divided into two groups: abnormal liver scan and mild fibrosis on liver bx, and abnormal liver scan and moderate to severe fibrosis on liver bx. Abnormal liver scans described nodular surface with coarse parenchyma. Outcomes included 3-year survival, freedom from cardiac allograft vasculopathy (CAV) as defined by stenosis ≥ 30% by angiography, freedom from Non-Fatal Major Adverse Cardiac Events (NF-MACE: myocardial infarction, new congestive heart failure, percutaneous coronary intervention, implantable cardioverter defibrillator/pacemaker implant, stroke), freedom from abnormal liver enzymes greater than 3 times normal.

Results: There was no significant difference for heart transplant 3-year survival, 3-year freedom from CAV and 3-year freedom from NF-MACE. However, there appear to be a strong trend towards poorer heart transplant survival in the abnormal scan and moderate to severe fibrosis group. There was no significant difference observed in abnormal liver enzyme levels (3x normal range) for all groups.

Conclusion: There appears to be a greater risk for reduced survival in patients with abnormal liver scans and moderate to severe fibrosis on liver bx. Further investigation with a larger population size is warranted.

Notes:

Endpoints Abnormal Scan + Mild Fibrosis (n=12) Abnormal Scan + Moderate/Severe Fibrosis (n=10) P-Value
3-Year Survival 100.0% 70.0% 0.051
3-Year Freedom from CAV 85.7% 100.0% 0.153
3-Year Freedom from NF-MACE 85.7% 88.9% 0.876
Freedom from AST>3X Normal 100.0% 100.0% 1.000
Freedom from ALT>3X Normal 91.7% 100.0% 0.350
Freedom from T-Bilirubin>3X Normal 91.7% 100.0% 0.350

CITATION INFORMATION: Mohan R, Patel J, Kittleson M, Chang D, Aintablian T, Czer L, Esmailian F, Kobashigawa J. Liver Evaluation for Heart Transplantation: Which Is Better, Noninvasive Scans or Liver Biopsy? Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Mohan R, Patel J, Kittleson M, Chang D, Aintablian T, Czer L, Esmailian F, Kobashigawa J. Liver Evaluation for Heart Transplantation: Which Is Better, Noninvasive Scans or Liver Biopsy? [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/liver-evaluation-for-heart-transplantation-which-is-better-noninvasive-scans-or-liver-biopsy/. Accessed March 4, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.